IMMP
Immutep Ltd Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website immutep.com
- Employees(FY) -
- ISIN US45257L1089
Performance
+6.49%
1W
+12.64%
1M
-22.05%
3M
-31.21%
6M
-14.58%
YTD
-0.49%
1Y
Profile
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.
Technical Analysis of IMMP 2024-12-02
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-13 19:15
- 2024-11-13 19:00
- 2024-10-28 20:00
Immutep Quarterly Activities Report Q1 FY25(Globenewswire)
- 2024-10-27 20:00
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS(Globenewswire)
- 2024-10-16 20:00
- 2024-10-09 20:00
- 2024-10-03 18:12
- 2024-10-02 20:00
- 2024-09-23 20:00
- 2024-09-17 20:00
- 2024-09-15 20:00
- 2024-08-19 20:00
- 2024-08-13 20:00
- 2024-08-06 20:00
Immutep to Participate in Upcoming Investor Conferences(Globenewswire)
- 2024-07-30 20:00
Immutep Quarterly Activities Report Q4 FY24(Globenewswire)
- 2024-07-21 20:00
- 2024-07-16 20:00
- 2024-07-14 20:39
- 2024-07-11 21:15
- 2024-07-11 19:41
- 2024-07-11 06:40
- 2024-07-02 20:00
- 2024-06-26 19:34
- 2024-06-24 20:00
- 2024-06-04 18:00
- 2024-06-02 08:38
- 2024-05-14 20:00
- 2024-05-01 20:00
- 2024-04-28 20:00
Immutep Quarterly Activities Report Q3 FY24(Globenewswire)
- 2024-04-23 20:00
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.